Acumen Pharmaceuticals, Inc. (ABOS): Total Assets
$122.83M
As of 2025-12-31
$116.01M
As of 2026-06-30
-14.5%
3-year compound annual growth
+22.6%
5-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $122.83M | -48.6% | 2026-03-26, Balance as of period end |
| 2024-12-31 | $238.99M | -22.9% | 2026-03-26, Balance as of period end |
| 2023-12-31 | $310.12M | +57.8% | 2025-03-27, Balance as of period end |
| 2022-12-31 | $196.59M | -14.6% | 2024-03-26, Balance as of period end |
| 2021-12-31 | $230.33M | +418.4% | 2023-03-27, Balance as of period end |
| 2020-12-31 | $44.43M | n/a | 2022-03-28, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Acumen Pharmaceuticals, Inc. (ABOS) | 2025-12-31 | $122.83M | -48.6% |
| Kalaris Therapeutics, Inc. (KLRS) | 2025-12-31 | $121.74M | n/m |
| Candel Therapeutics, Inc. (CADL) | 2025-12-31 | $125.19M | +17.2% |
| Humacyte, Inc. (HUMA) | 2025-12-31 | $116.37M | -15.6% |
| Pelthos Therapeutics Inc. (PTHS) | 2025-12-31 | $130.40M | n/m |
| Artiva Biotherapeutics, Inc. (ARTV) | 2025-12-31 | $130.94M | -37.5% |
| Zura Bio Ltd (ZURA) | 2025-12-31 | $113.95M | -36.5% |
| Lineage Cell Therapeutics, Inc. (LCTX) | 2025-12-31 | $112.58M | -0.6% |
| Palisade Bio, Inc. (PALI) | 2025-12-31 | $134.34M | n/m |
Compare ABOS, KLRS, CADL, HUMA side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗